Overview

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Status:
Completed

Trial end date:
2019-10-24

Target enrollment:

Participant gender:

Summary

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Angiopeptin
Lanreotide
Somatostatin